Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Eylea Market CAGR Outlook And Future Development
The eylea market has shown robust expansion in recent years. Its value is expected to rise from $10.51 billion in 2025 to $11.15 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.2%. This past growth can be attributed to several factors including the rising occurrence of age-related macular degeneration, an aging global demographic, the high clinical efficacy of anti-vegf drugs, an increase in ophthalmology specialty centers, and supportive reimbursement policies for retinal therapies.
The eylea market is projected for substantial expansion over the coming years. By 2030, its valuation is predicted to reach $14.79 billion, exhibiting a compound annual growth rate (CAGR) of 7.3%. Factors contributing to this anticipated growth during the forecast timeframe include a rising diabetic demographic, broader application in more retinal conditions, advancements in long-acting formulations, enhancements in drug delivery methods, and wider availability in developing economies. Key developments expected within the same period encompass longer-interval anti-VEGF treatments, a move towards using prefilled syringes, increased application in managing diabetic retinopathy, a rise in hospital-administered intravitreal procedures, and a greater emphasis on real-world data and patient results.
Get A Free Sample Report With In-Depth Market Insights:
Eylea Market Growth Drivers: What’s Behind The Acceleration?
The Eylea market is anticipated to grow due to the rising occurrence of ocular diseases. These conditions refer to eye issues that interfere with proper eye function, negatively affecting vision and clarity, often without symptoms until they become advanced. Eylea provides treatment for various ocular diseases, specifically targeting conditions like wet age-related macular degeneration (AMD) and glaucoma, which damage the retina or macula and impair vision. Its mechanism involves blocking the protein responsible for developing new, weaker blood vessels and reducing retinal swelling caused by blockages in blood vessels. For instance, according to the BrightFocus Foundation, in 2024, approximately 80 million people globally are living with glaucoma, and this figure is projected to rise to 111 million by 2040. Consequently, the increasing prevalence of ocular diseases is driving the Eylea market.
Eylea Market Segment Outlook: Which Categories Are Growing Fastest?
The eylea market covered in this report is segmented –
1) By Product: Prefilled Syringe Package, Vial Package
2) By Disorder: Wet Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Other Disorders
3) By Application: Hospitals, Retail Pharmacy, Other Applications
Subsegments:
1) By Prefilled Syringe Package: Single-Dose Prefilled Syringes, Multi-Dose Prefilled Syringes
2) By Vial Package: Single-Dose Vials, Multi-Dose Vials
Eylea Market Trends: What’s Defining The Industry’s Next Phase?
Key companies within the eylea market are concentrating on creating biologic medications, such as aflibercept biosimilar, to secure a competitive edge. An Aflibercept Biosimilar represents a biologically analogous version of the original aflibercept drug, engineered to exhibit no clinically relevant discrepancies and provide an economical substitute for managing specific eye conditions. For example, in September 2023, Biocon Biologics Ltd., an India-based biopharmaceutical enterprise, obtained marketing approval from the European Commission (EC) for YESAFILI, an Aflibercept biosimilar, across the European Union (EU). This authorization followed a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in July. YESAFILI, an ophthalmology solution, is developed for addressing various eye ailments, and its approval demonstrates its equivalence in terms of quality, safety, and efficacy when compared to the reference product Eylea (aflibercept).
Eylea Market Leading Companies And Competitive Benchmarking
Major companies operating in the eylea market are Regeneron Pharmaceuticals Inc., Bayer AG, Novartis AG, Roche Holding AG, Pfizer Inc., Amgen Inc., Sanofi S.A., AbbVie Inc., Alcon Inc., Genentech Inc., Johnson & Johnson, Samsung Bioepis Co. Ltd., Boehringer Ingelheim GmbH, Eisai Co. Ltd., Daiichi Sankyo Company Limited, Aerie Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Santen Pharmaceutical Co. Ltd., Allergan plc, BioMarin Pharmaceutical Inc.
View The Full Eylea Market Report:
Eylea Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the eylea market in 2025. Asia-Pacific is expected to be the fastest-growing region in the eylea market during the forecast period. The regions covered in the eylea market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
